Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations

Marco Savarese, Giuseppina Di Fruscio, Giorgio Tasca, Lucia Ruggiero, Sandra Janssens, Jan De Bleecker, Marc Delpech, Olimpia Musumeci, Antonio Toscano, Corrado Angelini, Sabrina Sacconi, Lucio Santoro, Enzo Ricci, Kathleen Claes, Luisa Politano, Vincenzo Nigro

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4%) patients carrying putative pathogenic changes in both alleles and 23 ANO5 heterozygotes (3%). The phenotypic spectrum is broader than expected, from hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the ANO5 gene. The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents a straightforward approach to overcome the difficulties of clinical heterogeneity of ANO5 patients, and to test, at the same time, many other genes involved in neuromuscular disorders.

Original languageEnglish
Pages (from-to)533-541
Number of pages9
JournalNeuromuscular Disorders
Volume25
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Limb-Girdle Muscular Dystrophies
Muscular Diseases
Mutation
Heterozygote
Genetic Testing
Genetic Association Studies
Genes
Exons
Alleles

Keywords

  • Anoctamin
  • LGMD2L
  • Limb girdle muscular dystrophy
  • Muscular dystrophy
  • Next generation sequencing
  • NGS screening
  • Targeted resequencing

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Next generation sequencing on patients with LGMD and nonspecific myopathies : Findings associated with ANO5 mutations. / Savarese, Marco; Di Fruscio, Giuseppina; Tasca, Giorgio; Ruggiero, Lucia; Janssens, Sandra; De Bleecker, Jan; Delpech, Marc; Musumeci, Olimpia; Toscano, Antonio; Angelini, Corrado; Sacconi, Sabrina; Santoro, Lucio; Ricci, Enzo; Claes, Kathleen; Politano, Luisa; Nigro, Vincenzo.

In: Neuromuscular Disorders, Vol. 25, No. 7, 01.07.2015, p. 533-541.

Research output: Contribution to journalArticle

Savarese, M, Di Fruscio, G, Tasca, G, Ruggiero, L, Janssens, S, De Bleecker, J, Delpech, M, Musumeci, O, Toscano, A, Angelini, C, Sacconi, S, Santoro, L, Ricci, E, Claes, K, Politano, L & Nigro, V 2015, 'Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations', Neuromuscular Disorders, vol. 25, no. 7, pp. 533-541. https://doi.org/10.1016/j.nmd.2015.03.011
Savarese, Marco ; Di Fruscio, Giuseppina ; Tasca, Giorgio ; Ruggiero, Lucia ; Janssens, Sandra ; De Bleecker, Jan ; Delpech, Marc ; Musumeci, Olimpia ; Toscano, Antonio ; Angelini, Corrado ; Sacconi, Sabrina ; Santoro, Lucio ; Ricci, Enzo ; Claes, Kathleen ; Politano, Luisa ; Nigro, Vincenzo. / Next generation sequencing on patients with LGMD and nonspecific myopathies : Findings associated with ANO5 mutations. In: Neuromuscular Disorders. 2015 ; Vol. 25, No. 7. pp. 533-541.
@article{28dbcdf3a59843d1b9e70c8224062a6f,
title = "Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations",
abstract = "We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4{\%}) patients carrying putative pathogenic changes in both alleles and 23 ANO5 heterozygotes (3{\%}). The phenotypic spectrum is broader than expected, from hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the ANO5 gene. The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents a straightforward approach to overcome the difficulties of clinical heterogeneity of ANO5 patients, and to test, at the same time, many other genes involved in neuromuscular disorders.",
keywords = "Anoctamin, LGMD2L, Limb girdle muscular dystrophy, Muscular dystrophy, Next generation sequencing, NGS screening, Targeted resequencing",
author = "Marco Savarese and {Di Fruscio}, Giuseppina and Giorgio Tasca and Lucia Ruggiero and Sandra Janssens and {De Bleecker}, Jan and Marc Delpech and Olimpia Musumeci and Antonio Toscano and Corrado Angelini and Sabrina Sacconi and Lucio Santoro and Enzo Ricci and Kathleen Claes and Luisa Politano and Vincenzo Nigro",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.nmd.2015.03.011",
language = "English",
volume = "25",
pages = "533--541",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Next generation sequencing on patients with LGMD and nonspecific myopathies

T2 - Findings associated with ANO5 mutations

AU - Savarese, Marco

AU - Di Fruscio, Giuseppina

AU - Tasca, Giorgio

AU - Ruggiero, Lucia

AU - Janssens, Sandra

AU - De Bleecker, Jan

AU - Delpech, Marc

AU - Musumeci, Olimpia

AU - Toscano, Antonio

AU - Angelini, Corrado

AU - Sacconi, Sabrina

AU - Santoro, Lucio

AU - Ricci, Enzo

AU - Claes, Kathleen

AU - Politano, Luisa

AU - Nigro, Vincenzo

PY - 2015/7/1

Y1 - 2015/7/1

N2 - We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4%) patients carrying putative pathogenic changes in both alleles and 23 ANO5 heterozygotes (3%). The phenotypic spectrum is broader than expected, from hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the ANO5 gene. The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents a straightforward approach to overcome the difficulties of clinical heterogeneity of ANO5 patients, and to test, at the same time, many other genes involved in neuromuscular disorders.

AB - We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4%) patients carrying putative pathogenic changes in both alleles and 23 ANO5 heterozygotes (3%). The phenotypic spectrum is broader than expected, from hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the ANO5 gene. The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents a straightforward approach to overcome the difficulties of clinical heterogeneity of ANO5 patients, and to test, at the same time, many other genes involved in neuromuscular disorders.

KW - Anoctamin

KW - LGMD2L

KW - Limb girdle muscular dystrophy

KW - Muscular dystrophy

KW - Next generation sequencing

KW - NGS screening

KW - Targeted resequencing

UR - http://www.scopus.com/inward/record.url?scp=84930536544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930536544&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2015.03.011

DO - 10.1016/j.nmd.2015.03.011

M3 - Article

AN - SCOPUS:84930536544

VL - 25

SP - 533

EP - 541

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 7

ER -